The potential implications include full pursuit of the commercialisation activities described for the proposed project's follow-on execution. Primarily, the commercial feasibility being the main of many implications to the project's execution. This includes us defining a clear 'route to market' when taking into account the geographic segments that have responded best to our current development and pre-clinical work activities. On the wider scheme of things, this proposed project's successful introduction of Volumizer will receive a diverse array of patient candidates, especially from the more vulnerable elderly demographic. Being able to enjoy the benefits of naturally based, risk-free, and effective facial filling, first starting out in Switzerland and the EU, before expansion into the U.S and East Asia. In addition to these, we were also able to confirm the industrial scale up necessities of Volumizer, and clinical validation required for first sales in Europe - and follow-on actions required to make this a reality including the regulatory pathways and technical expertise needed for smooth execution and transition into first sales. In terms of disruption, Volumizer is poised to become a core replacement to existing facial fillers which have continued to underperform, and setting the new standard on what fast and effective facial filler treatment will be like.